Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum

Gynecologic Oncology

Volumn 110, Issue 1, 2008, Pages 56-59

  Ramirez, Pedro T ^a   Schmeler, Kathleen M ^a   Milam, Michael R ^a   Slomovitz, Brian M ^b   Smith, Judith A ^a   Kavanagh, John J ^a   Deavers, Michael ^a   Levenback, Charles ^a   Coleman, Robert L ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Letrozole; Resistant ovarian and peritoneal cancer

Indexed keywords

CAPECITABINE; DOXORUBICIN; GEMCITABINE; LETROZOLE; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAPHORESIS; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FATIGUE; FEMALE; FOLLOW UP; HORMONAL THERAPY; HOSPICE CARE; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMED CONSENT; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NITRILES; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RECURRENCE; TAXOIDS; TREATMENT OUTCOME; TRIAZOLES;

EID: 45549096026     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.03.014     Document Type: Article

References (11)

1. American Cancer Society: cancer statistics. http://www.acs.org
2. Rao B.R., and Slotman B.J. Endocrine role in ovarian cancer. Endocr Relat Cancer 3 (1996) 309-326
3. Langdon S.P., Hawkes M.M., Lawrie S.S., et al. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer 62 (1990) 213-216
4. Langdon S.P., Crew A.J., Ritchie A.A., et al. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. Eur J Cancer 30A (1994) 682-686
5. O'Donnell A.J.M., MacLeod K.G., Burns D.J., et al. Estrogen receptor α mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 12 (2005) 851-866
6. Markman M., Iseminger K.A., Hatch K.D., et al. Tamoxifen in platinum-refractory ovarian cancer. A Gynecologic Oncology Group ancillary report. Gynecol Oncol 62 (1996) 4-6
7. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10 (1988) 1-10
8. Papadimitriou C.A., Markaki S., Siapkaras J., et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long term results of a phase II study. Oncology 66 (2004) 112-117
9. Bowman A., Gabra H., Langdon S.P., et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8 (2002) 2233-2239
10. Smyth J.F., Gourley C., Walker G., et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen-receptor positive patients. Clin Cancer Res 13 (2007) 3617-3622
11. Gronlund B., Hogdall C., Christensen I.J., et al. Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with paclitaxel-platinum?. Gynecol Oncol 94 (2004) 409-415